Fulcrum Therapeutics, Inc. filed an 8-K with the SEC on August 17, 2026, disclosing that it entered into an Agreement and Plan of Merger with Slate Medicines, Inc. on August 16, 2026, under which the two Delaware corporations would combine in a transaction structured as a tax-free reorganization.

Key Highlights

  • Ownership split at closing: Pre-merger Slate stockholders (other than the Investors) are expected to own approximately 55.9% of the combined company on a fully-diluted basis, the Investors approximately 39.1%, and pre-merger Fulcrum stockholders approximately 5.0%.
  • Implied valuations: The Exchange Ratio assumes a valuation for Fulcrum of $31.3 million (subject to net cash adjustment) and a valuation for Slate of $350.0 million, exclusive of the Concurrent Investment proceeds.
  • Concurrent Investment: A $245.0 million concurrent investment is contemplated as part of the transaction structure.
  • Cash dividend: Fulcrum expects to declare a cash dividend to pre-merger Fulcrum stockholders of $270 million in the aggregate, subject to adjustment as set forth in the Merger Agreement.
  • Name change planned: Fulcrum will seek stockholder approval to change its name to "Slate Medicines, Inc." and to effect a reverse stock split at a ratio to be mutually agreed upon.
  • Option treatment: All outstanding Fulcrum stock options will accelerate in full immediately prior to the effective time; options with an exercise price above $7.00 per share that are unexercised will be cancelled for no consideration at the effective time.

Fulcrum and Slate Medicines Merger: Key Terms and Conditions

According to the filing, Fulcrum Therapeutics (NASDAQ:FULC) entered into the Merger Agreement on August 16, 2026, with Merger Sub I and Merger Sub II, both wholly owned Fulcrum subsidiaries, and Slate Medicines, Inc. Under the structure disclosed, Merger Sub I will merge with and into Slate, with Slate surviving as the surviving corporation in the First Merger. Slate will then merge with and into Merger Sub II, with Merger Sub II continuing as a wholly owned Fulcrum subsidiary as the surviving entity of the Second Merger. The transaction is intended to qualify as a tax-free reorganization for federal income tax purposes, the filing states.

At the effective time, the filing discloses that each outstanding share of Slate Common Stock (par value $0.00001 per share) will be converted into the right to receive shares of Fulcrum Common Stock (par value $0.001 per share) based on an Exchange Ratio calculated under the Merger Agreement. Outstanding Slate options and warrants will be assumed by Fulcrum, subject to adjustment. For Fulcrum equity awards, the filing states that unvested restricted stock unit awards will vest in full immediately prior to the effective time, contingent on the closing, with holders receiving Fulcrum Common Stock in settlement.

Closing is subject to several conditions as disclosed in the filing, including approval by Fulcrum stockholders of the Fulcrum Voting Proposals, approval by Slate stockholders of the Merger Agreement, expiration or termination of the Hart-Scott-Rodino waiting period, Nasdaq listing approval for shares to be issued, effectiveness of a registration statement on Form S-4, effectiveness of the Nasdaq reverse stock split, Fulcrum's net cash at closing being no less than $0, and an executed Purchase Agreement for the $245.0 million Concurrent Investment being in full force and effect. The filing notes that each party has agreed to customary representations, warranties, and covenants, including non-solicitation of alternative acquisition proposals.

What Was Disclosed

Fulcrum Therapeutics filed an 8-K reporting its August 16, 2026 entry into a merger agreement with Slate Medicines, covering ownership percentages, implied valuations, a planned $270 million cash dividend to existing Fulcrum stockholders, equity award treatment, and required closing conditions.